In a 214-patient interim analysis from the single-arm Phase IIb COPERNICUS study, first-line subcutaneous amivantamab plus lazertinib with anticoagulation and enhanced dermatologic prophylaxis produced rash, administration-related reactions, and venous thromboembolism rates of 25%, 3%,…
Legend Biotech appointed Ingrid Zhang chief executive officer and principal executive officer effective September 15, 2026, following a comprehensive board-led search. She succeeds interim CEO Alan Bash, who had served since July and now…
The final overall-survival analysis of PAPILLON reported median survival of 34.3 months with first-line amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, but the intent-to-treat comparison was not statistically significant (HR 0.87; P=0.307)….
The European Commission has expanded the approval of Johnson & Johnson’s teclistamab (Tecvayli), a BCMA-targeted bispecific antibody, in combination with daratumumab, to patients with relapsed or refractory multiple myeloma who have received at least…
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President and Worldwide Chairman, Innovative Medicine. Tom Cavanaugh, currently Company Group Chairman for North America, Innovative Medicine, will succeed her and join…
FDA granted Priority Review to Johnson & Johnson’s supplemental application for subcutaneous amivantamab plus hyaluronidase in recurrent or metastatic head-and-neck squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 therapy. The milestone accelerates review but…
Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, adding the Firelink degrader antibody conjugate platform for KRAS-driven and other difficult solid tumors. Closing is a meaningful update to the June…
Johnson & Johnson entered strategic agreements with Sail Biomedicines to advance an immune-mediated-disease program and Sail’s broader in vivo CAR-T platform. J&J will make $785 million in total initial payments, including a $465 million…
Legend Biotech disclosed that Ying Huang resigned as chief executive officer and a director, effective July 24, after notifying the board on July 22. He is expected to advise the company through August. The…
Europe’s medicines committee recommended Icotyde, or icotrokinra, for adults and adolescents aged 12 years and older weighing at least 40 kilograms with moderate-to-severe plaque psoriasis. The July 24 opinion covers a once-daily oral peptide…
